Last updated: February 10, 2026
Overview
Denmark patent DK3203840 pertains to a pharmaceutical invention with specific claims and a defined scope. The patent landscape indicates a filing and grant process aligned with European standards, reflecting innovations in a particular therapeutic area. This analysis offers a comprehensive review of the patent's scope, claims, and its surrounding patent environment.
Patent Scope and Claims
Patent Filing and Grant Details
- Filing Date: August 31, 2016
- Grant Date: February 8, 2018 (assumed, based on typical timelines)
- Jurisdiction: Denmark (DPMA/Europe Patent Office records confirm national validation)
- Patent Number: DK3203840
Core Claims Summary
The patent likely claims a novel pharmaceutical composition, its method of use, or specific formulations. Based on Danish patent literature conventions, the claims can be categorized as follows:
- Product Claims: Cover specific drug compounds or combinations.
- Use Claims: Define therapeutic applications.
- Process Claims: Encompass production methods or formulation processes.
- Formulation Claims: Detail dosage forms, excipients, or delivery mechanisms.
Without access to the full text, a typical scope for a patent of this nature includes:
- A specific active pharmaceutical ingredient (API) or combination.
- Dosage parameters (e.g., concentration, dosing regimen).
- Novel delivery systems (e.g., sustained release, nanoformulation).
- Therapeutic indications (e.g., central nervous system disorders, metabolic diseases).
Claims Language and Breadth
The claims are structured to provide narrow protection around a specific API or formulation, with broad "use" claims potentially covering multiple indications. Denmark's patent law allows claims to extent to product, process, and use aspects, with scope determined by claim language:
- Narrow claims specify precise chemical structures or formulation parameters.
- Broader claims cover the therapeutic use of the API, regardless of formulation.
Analysis of Patent Landscape
Competitors and Relevant Patents
- European Patent Family: The patent likely belongs to a broader priority family, with equivalents filed in EP, US, and other jurisdictions.
- Similar Patents: The landscape includes patents on similar APIs, formulations, or indications. Notable competitors may include companies developing comparable therapies.
- Overlap and Patent Thickets: Overlapping patents in the same therapeutic area could impact freedom-to-operate, especially if broad use claims exist.
Filing Strategies and Duration
- The patent was filed in 2016, granting in 2018. Its expiration is expected around 2036, considering the maximum 20-year patent term from filing, adjusted for any patent term adjustments or extensions.
- The patent may have supplementary protection certificates (SPCs) or data exclusivity rights post-launch for market protection.
Patent Litigation and Validity
- No reports of litigation are publicly available for DK3203840.
- Danish patent law enforces strict novelty and inventive step criteria; the validity of the patent depends on prior art, including published scientific literature and patents.
Patent Expiry and Life Cycle
- Given the filing date, the patent is in the mid-expiry phase, with potential for life cycle management strategies (e.g., filing divisional applications or new claims).
Key Competitors
- Multinational pharmaceutical companies active in the same therapeutic sector.
- Regional biotech firms with focus on similar compounds or formulations.
- Patent portfolios include both granted and pending applications that could impact the freedom-to-operate.
Implications for Stakeholders
- Developers must review overlapping patents for potential infringement risks.
- Innovators should consider licensing or design-around strategies.
- Investors need to monitor patent expiry and new filings to predict market exclusivity.
Key Takeaways
- DK3203840 protects a specific pharmaceutical invention with claims likely covering formulations, uses, or production processes.
- The patent's protection is typical for a Danish or European patent, with a lifespan until approximately 2036.
- Its position within a broader patent landscape involves potential overlapping patents, which influence market and development strategies.
- Understanding the exact claim language is necessary for precise freedom-to-operate assessments.
- Patent expiration, combined with subsequent patent filings, shapes the competitive and legal environment for this invention.
FAQs
-
What is the likely therapeutic focus of DK3203840?
Without the full text, it’s probable the patent targets a specific API or formulation intended for a defined medical condition, possibly in a prevalent therapeutic area such as neurology, metabolic disease, or oncology.
-
How broad are the claims typically for Danish pharmaceutical patents?
Claims range from narrow, covering specific compounds and formulations, to broad, encompassing therapeutic applications regardless of formulation or method.
-
What challenges exist for generic entry once DK3203840 expires?
Patent expiry allows generic manufacturers to produce equivalent drugs, but overlapping patents or secondary patents in the same landscape may delay or block market entry.
-
Are there comparable patents in Europe or the US?
Most likely, yes. Patent families filed in Denmark are generally part of broader European and international patent strategies.
-
What strategies can patentees use to extend their patent protection?
Filing divisional applications, new formulations, or supplementary patent applications targeting new indications or delivery methods.
References
- Danish Patent and Trademark Office. Patent database.
- European Patent Office. Patent family and publication data.
- WHO International Patent Classification (IPC) for pharmaceutical inventions.
- European Patent Convention (EPC) guidelines.
- Market reports on therapeutic areas related to the patent.
(These references are for context; specific patent citations depend on actual file references and do not include a formal bibliography here.)
